Clinical trial · Observational
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)
NCT01385150CI-TRIAL-00027694completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| liquid chromatography | Other | — | UNRESOLVED |
| mass spectrometry | Other | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| protein analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Absence of serum 2HG in all samples without an IDH mutation
- timeFrame
- 1 day
Secondary outcomes (1)
- measure
- Relationship between 2HG level and survival outcomes
- timeFrame
- 1 day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 60 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Morphologically confirmed acute myeloid leukemia (AML) * Newly diagnosed with AML * Serum samples from patients enrolled on the ECOG-1900 clinical trial between 2002 and 2008 * Patients with or without isocitrate dehydrogenase (IDH) mutations PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Received 2 different doses of standard induction chemotherapy on ECOG-1900
References
Publications (0)
Data not yet available
No reference posted for this study.